Women's Health
Since multigene panel testing (MGPT) for hereditary cancer syndromes became available in 2012, multiple laboratories have offered various MGPT options ranging in size and scope. Smaller panels consisting of “high-risk” genes are favored by some clinicians due to the availability of management guidelines, lower chance of an incidental finding, and lower variant of uncertain significance (VUS) rates; whereas larger panels are favored by others due to their comprehensive nature. Since 2012, utilization of MGPT has increased while single-syndrome testing has decreased across many physician specialties. This study aims to explore the utilization of breast cancer (BC)-specific and comprehensive cancer panels among clinicians of various specialties in breast cancer patients.